EUVIMEDEUVIMED entdecken
EditorialKommentar

Cladribine for pulmonary Langerhans cell histiocytosis: first prospective evidence and a new therapeutic horizon

Sergio Harari iD, Robert Vassallo iD

European Respiratory Journal · 2026-05 · 67 (5) · 2600040

DOI: 10.1183/13993003.00040-2026 ↗

Kurz gefasst

Editorial in der Zeitschrift European Respiratory Journal, online erschienen am 21.05.2026. Verfasst von Sergio Harari und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy sergio@sergioharari.it. Die Arbeit nennt 10 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy sergio@sergioharari.it.
  • Division of Pulmonary and Respiratory Intermediate Care Unit, MultiMedica IRCCS, Milan, Italy.
  • Division of Pulmonary and Critical Care Medicine, Departments of Medicine, Physiology and Biomedical Engineering, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.

ORCID-Profile: Sergio Harari, Robert Vassallo

Zitieren

APA

Harari, S., & Vassallo, R. (2026). Cladribine for pulmonary Langerhans cell histiocytosis: first prospective evidence and a new therapeutic horizon. European Respiratory Journal, 67(5), 2600040. https://doi.org/10.1183/13993003.00040-2026

Vancouver

Harari S, Vassallo R. Cladribine for pulmonary Langerhans cell histiocytosis: first prospective evidence and a new therapeutic horizon. European Respiratory Journal. 2026;67(5):2600040. doi:10.1183/13993003.00040-2026

BibTeX
@article{Harari2026,
  author = {Harari, Sergio and Vassallo, Robert},
  title = {Cladribine for pulmonary Langerhans cell histiocytosis: first prospective evidence and a new therapeutic horizon},
  journal = {European Respiratory Journal},
  year = {2026},
  volume = {67},
  number = {5},
  pages = {2600040},
  doi = {10.1183/13993003.00040-2026}
}
Kostenlos starten →